Zealand Pharma finds all patients for phase III study
A total of 108 patients have been enrolled in Zealand Pharma's crucial trial of glepaglutide as a treatment of short bowel syndrome.
by marketwire, translated by daniel pedersen
Biotech company Zealand Pharma has recruited all 108 patients required for a phase III study of its drug candidate glepaglutide, which is meant to treat short bowel syndrome, the company announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma reports positive data from phase Ib trial
For subscribers
.jpg&w=384&q=75)
